This article is more than 5 years old. Information may no longer be current.
DAPC
Diabetic Atherosclerosis Prevention by Cilostazol
Click Here to Manage Email Alerts
Trial assessed effects of cilostazol vs. aspirin for the inhibition of carotid intima-media thickness progression in patients with type 2 diabetes.
Design: prospective, randomized
Patients: 329
Centers: 22
Countries: Japan, Korea, China, Philippines
RESULTS: Patients assigned to cilostazol showed a greater regression in maximum left (–0.088 ± 0.260 vs. 0.059 ± 0.275 mm, P<.001), maximum right (–0.042 ± 0.274 vs. 0.045 ± 0.216 mm, P=.003), mean left (–0.043 ± 0.182 vs. 0.028 ± 0.202 mm, P=.004) and mean right (–0.024 ± 0.182 vs. 0.048 ± 0.169 mm, P<.001) common carotid artery intima-media thickness vs. those assigned to aspirin therapy. Additionally, researchers reported no significant differences between the two groups in major CV events.
Published in: Circulation. 2010;121:2584-2591.
Click here to read more about the DAPC trial.